Repligen (NASDAQ:RGEN) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Repligen (NASDAQ:RGEN) announced its earnings results on Tuesday. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09, FiscalAI reports. The business had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The company’s revenue was up 11.9% on a year-over-year basis. During the same period last year, the business posted $0.26 EPS. Repligen updated its FY 2026 guidance to 2.030-2.090 EPS.

Here are the key takeaways from Repligen’s conference call:

• Strong Q2 results and raised guidance: Revenue reached $204 million, up 12% reported and 13% organically, while adjusted EPS rose 46% to $0.54. Repligen raised its full-year organic growth outlook to 10.5%–13.5% and adjusted EPS guidance to $2.03–$2.09.
• Broad-based franchise momentum: Proteins grew 50%, Analytics increased more than 30%, and Chromatography delivered low-double-digit growth. Emerging biotech grew at a high-teens rate for the fifth consecutive quarter, suggesting improving customer funding and demand.
• Margin expansion continued: Adjusted operating margin expanded 460 basis points to 16.7%, supported by volume leverage, pricing, product mix, and manufacturing efficiencies. The company raised full-year operating margin guidance to 15.7%–16% while remaining on track for its 30% adjusted EBITDA margin target by 2030.
• BioLife acquisition expected to add growth and earnings: Management said the planned acquisition will accelerate Repligen’s cell-therapy strategy and add at least $20 million of synergies and $0.05 of adjusted EPS accretion in year one, rising to at least $30 million and $0.25 in year two. The transaction is not included in current 2026 guidance and remains subject to customary approvals.
• Filtration remains a near-term weak spot: Filtration revenue grew only slightly as gene-therapy exposure, customer inventory reductions, site-readiness delays, and the Polymem divestiture weighed on results. Management expects some of these pressures to persist into Q3, although ATF order momentum and normalization are anticipated in Q4 and 2027.

Repligen Stock Up 1.1%

NASDAQ:RGEN traded up $1.57 during mid-day trading on Thursday, reaching $142.80. The stock had a trading volume of 391,255 shares, compared to its average volume of 1,018,244. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.78. The company has a market capitalization of $8.06 billion, a price-to-earnings ratio of 195.70, a price-to-earnings-growth ratio of 2.80 and a beta of 1.06. Repligen has a 1-year low of $100.99 and a 1-year high of $175.77. The stock’s 50 day simple moving average is $133.54 and its two-hundred day simple moving average is $131.70.

Insider Buying and Selling

In other news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Repligen

A number of hedge funds have recently added to or reduced their stakes in the business. Measured Wealth Private Client Group LLC bought a new stake in Repligen during the third quarter valued at $29,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen during the fourth quarter worth $36,000. Itau Unibanco Holding S.A. lifted its position in shares of Repligen by 38.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after buying an additional 104 shares during the last quarter. Johnson Financial Group Inc. acquired a new position in shares of Repligen in the 3rd quarter valued at about $65,000. Finally, Wilmington Savings Fund Society FSB boosted its holdings in shares of Repligen by 2,750.0% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 495 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen News Roundup

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Strong Q2 performance: Repligen reported revenue of approximately $204.1 million, up 11.9% year over year and ahead of the $201.6 million consensus estimate. Adjusted EPS of $0.54 exceeded expectations of $0.45, while organic growth reached 13%. Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
• Positive Sentiment: Guidance raised: Management increased its 2026 organic revenue-growth forecast to 10.5%-13.5% and adjusted diluted EPS guidance to $2.03-$2.09. The company cited continued order strength and better visibility into the second half of the year. Repligen jumps after Q2 beat and higher 2026 outlook
• Positive Sentiment: More bullish analyst views: Wells Fargo raised its price target from $180 to $185 and maintained an Overweight rating. JPMorgan also lifted its target from $165 to $175 and reiterated Overweight. The broader consensus target implies roughly 25.7% upside, though price targets are not reliable guarantees. Wall Street Analysts Believe Repligen Could Rally
• Neutral Sentiment: BioLife Solutions deal: Management has characterized the planned acquisition as potentially supportive of long-term revenue growth, margins and earnings, but investors still face execution and transaction risks. Repligen Held an M&A Call With BioLife Solutions
• Negative Sentiment: Valuation and selling pressure: Repligen trades at a very high earnings multiple, and Canaccord Genuity maintained a Hold rating with a $145 target, citing a full valuation. Reported recent insider activity also showed sales by the CEO and CFO, which may temper bullish sentiment.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Benchmark upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research note on Tuesday, July 7th. Wolfe Research started coverage on Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price for the company. Weiss Ratings raised Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 14th. Citigroup upgraded Repligen to a “buy” rating in a research note on Tuesday, July 7th. Finally, Rothschild & Co Redburn set a $160.00 price target on Repligen and gave the company a “buy” rating in a report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average price target of $166.43.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.